Neuromodulation: Spinal Cord Stimulation Devices Market

This report provides an overview of chronic pain and treatment with implantable neuromodulation systems called spinal cord stimulation (SCS) devices. Implantable SCS devices have been utilized with a high degree of success for decades, particularly in the US but also in Europe and increasingly in other regions, where they have become a life-changing therapy option for thousands of suffering patients.

Implantable SCS devices are similar in design and function to cardiac pacemakers but are prescribed for treating neuropathy or nerve damage in patients seeking long-term alleviation of excruciating pain. Specifically, SCS devices have primarily been used as a last option for treating chronic, intractable neuropathic pain of the trunk and/or limbs, such as debilitating back or leg pain typically experienced in patients following back surgery or failed back surgery or due to an accident/injury or disease.

In the US, the growing pain medication (opioid) addiction epidemic has ignited a search for safer and more effective, non-drug pain therapy alternatives. The opioid epidemic has helped increase awareness of SCS therapy, spurring steady growth in global SCS revenues to a value approaching $2.7bn (see Chapter 3).

Neuromodulation technology is steadily evolving. Despite the COVID-19 pandemic, the SCS devices market has witnessed an exciting era defined by advanced, next-generation technologies resulting in superior outcomes. A wide variety of SCS waveforms and stimulation therapies have become available to customize pain therapy in order to better address the unique challenges of chronic pain, which is extremely difficult to manage, evolves, and is unique per patient. Technological innovation and a procedural surge addressing pent-up demand and the backlog of surgeries have started boosting the SCS market and is likely to continue in the near future. .

This report provides the following useful information:

• an overview of chronic pain

• new and emerging SCS technologies

• product portfolios and pipelines

• in-depth market and competitive analyses.

Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets.

If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].